/
We currently rely and expect to continue to rely on third parties for the manufacture of our product candidates for preclinical and clinical testing and for commercial supply of PYRUKYND and AQVESME and any product candidate for which we may obtain marketing approval. Any performance failure on the part of our existing or future third-party manufacturers could delay clinical development, market…
The business is unprofitable at the operating level (-873.87% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 48.0% YoY with margins expanding 292.6pp.
Negative free cash flow of -$377M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$66M
▲ +48.0% YoY
Net Income (TTM)
-$423M
▼ -161.3% YoY
Op. Margin
-719.97%
▲ +292.6pp YoY
ROIC
-29.32%
▲ +0.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$385M
▲ +3.6% YoY
Op. Cash Flow (TTM)
-$380M
▲ +4.3% YoY
Net Debt
-$701M
Net Cash Position
Cash & Equiv.
$737M
Continue Research